Dariusz Pytel to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications Dariusz Pytel has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Connection Strength
0.178
-
BCR/ABL stimulates WRN to promote survival and genomic instability. Cancer Res. 2011 Feb 01; 71(3):842-51.
Score: 0.095
-
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair. Mutat Res. 2006 Jan 31; 603(1):74-82.
Score: 0.067
-
[Tyrosine kinases. New target of anticancer therapy]. Postepy Biochem. 2005; 51(3):251-60.
Score: 0.016